Timothy R. Wright
Independent DirectorMr. Timothy R. Wright, also known as Tim, MBA, is Independent Director of Protagenic Therapeutics, Inc. since July 18, 2025. He is Member of Advisory Board at Biosortia Pharmaceuticals, Inc. He served as Lead Independent Director of Protagenic Therapeutics, Inc. until May 15, 2025 and served as its Independent Director since November 23, 2022 until May 15, 2025. He has been Executive Chairman of the Board at Isosceles Pharmaceuticals, Inc. since May 2019. Mr. Wright was a Director of MiMedx Group, Inc. from June 17, 2019 to September 2022. He had been the Chief Executive Officer at MiMedx Group, Inc. since joining on May 13, 2019 until September 2022. Mr. Wright had been President and Chief Executive Officer at Moffitt Genetics Corporation, Inc. since August 23, 2017. He is the senior advisor to the Wake Forest Institute of Regenerative Medicine and a Director of BIORG. Mr. Wright served as the President & Chief Executive Officer of M2Gen Corp. between July 2017 and September 2018 and serves as its Director. Mr. Wright served as Executive Vice President of Business Development, Strategy and Commercial Innovation at Teva Pharmaceutical Industries Limited since April 13, 2015 until April 18, 2017. Mr. Wright served as Chairman and Interim Chief Executive Officer at Curaxis Pharmaceutical Corporation from July 2011 to July 2012 and from July 2011 to July 2012 respectively. He served as Director of Curaxis Pharmaceutical Corporation from July 2011 to July 2012. Mr. Wright has of executive experience in the pharmaceutical, biotech and medical devices industries. Mr. Wright has experience of the pharmaceutical industry holding senior management positions in the United States, Canada and Europe. He is the Founder of Mortimer Capital. He has a pharmaceutical background in P&L management, business restructuring/transformation, commercialization, life cycle management and leadership development. He served as President of Pharmaceuticals Division at ZeeCRO Inc. since April 2004. He served as Chief Executive Officer and President at Covidien and Elan. He served as Interim President and Interim Chief Executive Officer of ZeeCRO Inc. since November 9, 2004. He served as Chief Executive Officer at IS Pharma Limited since September 2005. He served as President of Global Commercial Operations at Elan Corporation, plc since July 2002 until 2004. Mr. Wright served as Executive Vice President, Mergers and Acquisitions, Strategy and Innovation for Teva Pharmaceutical Industries Ltd. (“Teva”), a pharmaceutical company specializing in generic medicines, from April 2015 until August 2017. At Elan, he was instrumental in the establishment, significant growth and ultimate successful divestment of their European business. He served as Senior Vice President of Cardinal Health. Mr. Wright has experience in senior management positions in the product development and marketing divisions of both Smithkline Beecham and Pfizer. Prior thereto, he served in a number of senior positions with Dupont Merck Pharmaceuticals, Inc. in the United States, Canada and in Europe, including Senior Vice President, Strategy & Corporate Business Development from 1996 to 1999, Vice President, Strategic Marketing & Operations – Europe from 1995 to 1996, President & Chief Executive Officer, Toronto, Canada from 1993 to 1995 and Vice President, Marketing from 1990 to 1993. Mr. Wright has focused exclusively on the healthcare industry, amassing a range of experience in pharmaceutical executive leadership, sales and marketing, strategic planning, mergers and acquisitions and finance. He served as Interim Chief Executive Officer & President and Chief Operating Officer at AAI Pharmaceuticals /Xanodyne from 2004 to 2007. He joined aaiPharma from Elan Biopharmaceuticals where he served as President of Global Commercial Operations and was instrumental in creating and executing the Elan recovery plan. He served as President, Europe, Japan & ROW and Executive Vice President, Business Development & Licensing at Elan from 2001 to 2002. Prior to his experience with Elan, Mr. Wright held a number of senior management and executive positions with well-known healthcare companies including Cardinal Health and held senior management positions with DuPont Pharma and DuPont Merck from 1984 to 1999, where he served as brand champion of the company’s organ transplantation and plasma volume expansion businesses and eventually became global Senior Vice President, Strategy and Corporate Business Development, as well as President of DuPont Merck, Canada and Senior VP DuPont Merck, Europe Heading up Marketing and Business Development. He served as President of Imaging Solutions and Pharmaceutical Products at Mallinckrodt, LLC. He served as Senior Vice President and President of the Imaging Solutions and Pharmaceutical Products Sector at Covidien plc from February 2007 to December 2, 2010. Mr. Wright was appointed President of Tyco healthcare Imaging and Pharmaceuticals businesses in 2007. He restructured the Imaging and Pharmaceuticals business, divesting Mallinckrodt Baker and then prepared the company’s IPO. He served as Senior Vice President of Strategy and Corporate Business Development at DuPont Pharmaceuticals. He served as Chief Operating Officer of Xanodyne Pharmaceuticals, Inc. until May 2006. He serves as Chairman of ParagonRx International, LLC. He has been an Independent Director of Agenus Inc. since December 17, 2006 and has been its Lead Director since 2009. Mr. Wright joined the Agenus Inc. on December 07, 2006. He served as a Director of IS Pharma Limited since October 17, 2005. He serves as Director of Port la Salle Management Limited. He served as Director of ZeeCRO Inc. since May 2004. He served as Director at AAI Pharmaceuticals /Xanodyne from 2004 to 2007. He served as a Director of Sinclair Pharma plc from May 23, 2011 to May 31, 2012. He served as a Non-Executive Director of PAION Holdings UK Limited until September 16, 2003. He is the Founder of the Drug Discovery and Development Institute for the Ohio State University Comprehensive Cancer Center and serves as its Chairman. He is a Member of Board The Ohio State University Innovation Foundation, the technology transfer arm of OSU’s Comprehensive Cancer Center. Over his career, Mr. Wright has served on nine Boards of Directors, five in North America and four in Europe and Asia. Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011 until May 2019 of which he was the Founder. Mr. Wright previously held several executive roles at Covidien (now Medtronic) and Teva Pharmaceuticals Industries Ltd. Mr. Wright was the founding Partner of The Ohio State University Comprehensive Cancer Drug Development Institute. Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute. He sits on The Ohio State University College of Pharmacy Dean’s Corporate Council. Mr. Wright received a Bachelor
Positions
- Company NameProtagenic Therapeutics, Inc.Stock CodePTIXPositionIndependent Director
